Wende Hutton

General Partner

2004 - Current

Investor in Med tech/Digital Health and Biopharmaceuticals. Recent boards include Labrys Biologics (acquired by Teva), Dermira (DERM), Transcend Medical (acquired by Alcon/Novartis) and Chimerix (CMRX). Current boards include Antiva Biosciences, Glooko, OncoResponse, Qlaris Bio and Hyalex Orthopeadics.

supporter

2013 - 2013

General Partner

1993 - 2001

General Manager, Transgenic Lab Products

1991 - 1992

Director, International Business Unit; Dir of Business Development; Marketing

1986 - 1990